男性类风湿关节炎患者心血管死亡风险显著高于女性
研究在2019年5月至2022年12月期间对125例新诊断类风湿关节炎患者(平均年龄56岁,78%为女性)进行心血管疾病及危险因素筛查,评估10年心血管死亡风险及预防性用药启动情况。结果显示男性高/极高风险比例为50%,女性仅4%,仅26%的高/极高风险患者启动降压或他汀类药物治疗。
要点
- 新诊断类风湿关节炎患者中男性高/极高10年心血管死亡风险为50%,女性仅4%。
- 筛查发现男性高血压57%、女性43%,男性血脂异常36%、女性32%。
- 仅26%的高/极高风险患者筛查后启动降压或他汀类药物治疗。
核心结论
- 新诊断类风湿关节炎患者常存在心血管疾病风险增加,尤其是男性患者,大部分存在未诊断和未治疗的高血压和高胆固醇血症。
- 即使进行结构化筛查并告知患者和全科医生,高危患者心血管危险因素的治疗仍不充分。
- 心血管风险筛查需成为类风湿关节炎患者标准诊疗的一部分,并明确初级和二级诊疗之间的责任分工。
- 需要提高类风湿关节炎患者自身和全科医生对心血管疾病风险筛查重要性的认识,以最终降低患者的心血管负担。
- 显然,全科医生和风湿科医生之间急需更好的协作以降低患者的心血管负担。
研究设计与样本
- 研究在门诊风湿科作为标准诊疗的一部分,于2019年5月至2022年12月期间对年龄40-70岁的新近诊断类风湿关节炎患者,在诊断后第一年内进行心血管疾病及危险因素筛查。
- 筛查包括体格检查测量血压和实验室血脂谱检测,所有患者及其全科医生收到心血管风险概况和计算的10年心血管死亡风险概览。
- 心血管风险定义为低(<1%)、中(1-5%)、高(5-10%)和极高(>10%)。
- 通过国家药房网络查询患者筛查后是否启动预防性用药。
主要发现
- 共纳入125例类风湿关节炎患者,平均年龄56岁,78%为女性,筛查时类风湿关节炎中位病程为6个月。
- 6例患者(5%)表示既往已筛查并使用降压药物。
- 筛查时男性患者高血压为57%、女性为43%,男性血脂异常为36%、女性为32%。
- 目前吸烟者男性为46%、女性为21%。
- 高或极高10年心血管死亡风险见于50%的男性患者,但仅见于4%的女性患者。
临床怎么用
- 原文结论指出心血管风险筛查需成为类风湿关节炎患者标准诊疗的一部分,并明确初级和二级诊疗之间的责任分工。
- 原文结论指出需要提高类风湿关节炎患者自身和全科医生对心血管疾病风险筛查重要性的认识。
- 原文结论指出全科医生和风湿科医生之间急需更好的协作以降低患者的心血管负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with rheumatoid arthritis (RA) are at an increased risk for developing cardiovascular diseases. While advice regarding cardiovascular risk screening and management in RA patients has been incorporated in several guidelines in recent years, its implementation and adherence is still poor. OBJECTIVES: To assess the cardiovascular disease risk in new diagnosed RA patients and evaluate whether advice to initiate preventive medical treatment of high risk patients was followed. METHODS: All patients with a recent diagnosis of RA, aged 40-70 years, were screened between May 2019 and December 2022 for cardiovascular diseases and risk factors within the first year after diagnosis at the outpatient rheumatology clinic, as part of standard care. Screening included a physical examination with blood pressure measurement, and laboratory tests with lipid profile tests. All patients and their general practitioner (GP) received an overview with their cardiovascular risk profile and a calculated 10-year cardiovascular mortality risk. Cardiovascular risk was defined as low (<1%), intermediate (1-5%), high (5-10%) and very high (>10%). The national pharmacy network was consulted to check whether or not patients started preventive medication after screening. RESULTS: A total of 125 RA patients was included in this study. The mean age was 56 years and 78% was female. Median RA disease duration at screening was 6 months. Six patients (5%) indicated to have been screened before, and used antihypertensive medication. During screening, hypertension was found in 57% of male patients and 43% of female patients and dyslipidemia was found in 36% in male and 32% in female patients. 46% of male patients and 21% of female patients currently smoked. A high or very high 10-year cardiovascular mortality risk was found in 50% of male patients, but in only 4% of female patients. Only 26% of (very) high risk patients started antihypertensive or statin medication after screening. CONCLUSIONS: An increased cardiovascular disease risk is often present in newly diagnosed RA patients, especially male patients, with a large proportion having undiagnosed and untreated hypertension and hypercholesterolemia. Even with structural screening and informing of the patients and GPs, treatment of cardiovascular risk factors in high risk patients remains insufficient. CV risk screening needs to be part of standard care for RA patients, with clear agreement on the responsibilities between primary and secondary care. Awareness of the importance of CVD risk screening needs to improve among both RA patients themselves and the GPs to ultimately reduce the cardiovascular burden of our patients. Obviously, a better collaboration between GPs and rheumatologists is urgently needed to lower the cardiovascular burden of our patients.
引用
- Raadsen R, Hansildaar R, van Kuijk AWR, et al. Male rheumatoid arthritis patients at substantially higher risk for cardiovascular mortality in comparison to women. Semin Arthritis Rheum. 2023. PMID: 37356211. doi:10.1016/j.semarthrit.2023.152233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。